Associated tags: Medicine, Patient, Intelligence, Network medicine, Therapy, Rheumatoid arthritis, Pharmaceutical industry, RA, Sickle Cell Anemia, a Molecular Disease, Degenerative disease, Protocol, Other Health, Center for Medicare and Medicaid Innovation, Precision medicine, TNF inhibitor, TNF, Methotrexate, Trellis, HIV disease progression rates, MAC
Retrieved on:
Thursday, September 7, 2023
Other Health,
Software,
Managed Care,
Pharmaceutical,
Oncology,
White House,
Federal Government,
Medical Devices,
Technology,
Health Insurance,
Biotechnology,
Health,
Public Policy,
Government,
CMS,
RA,
Failure,
Centers for Medicare & Medicaid Services,
LCD,
Medicare,
MAC,
Center for Medicare and Medicaid Innovation,
Patient,
Medicine,
Rheumatoid arthritis,
Pharmaceutical industry Scipher Medicine Corporation, a precision immunology company matching each patient with their most effective therapy, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), and Centers for Medicare and Medicaid Services (CMS) published a local coverage determination (LCD) for molecular biomarker testing to guide targeted therapy selection in rheumatoid arthritis (RA) patients.
Key Points:
- Scipher Medicine Corporation, a precision immunology company matching each patient with their most effective therapy, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), and Centers for Medicare and Medicaid Services (CMS) published a local coverage determination (LCD) for molecular biomarker testing to guide targeted therapy selection in rheumatoid arthritis (RA) patients.
- The coverage decision includes PrismRA, Scipher’s innovative molecular diagnostic test that guides treatment selection for patients with RA.
- “Precision medicine will now be accessible to many patients suffering from rheumatoid arthritis, a potentially debilitating disease if not treated with the right therapy,” Scipher Medicine CEO Alif Saleh said.
- “This coverage decision not only represents a significant benefit for patients today but also ushers in a new era of precision medicine in autoimmune diseases.”
Access to PrismRA will benefit eligible patients within Medicare who covers approximately 66 million lives in the United States.
Retrieved on:
Tuesday, October 12, 2021
Twitter,
Technology,
Network medicine,
Risk,
Degenerative disease,
Protocol,
Sickle Cell Anemia, a Molecular Disease,
RA,
GLOBE,
LinkedIn,
HIV disease progression rates,
Precision medicine,
TNF inhibitor,
Rheumatoid arthritis,
TNF,
Therapy,
Methotrexate,
Partnership,
Intelligence,
Patient,
Trellis,
Pharmaceutical industry,
Medical imaging Scipher Medicine, the manufacturer of PrismRA, is a precision immunology company helping providers determine the most effective therapy for their patients.
Key Points:
- Scipher Medicine, the manufacturer of PrismRA, is a precision immunology company helping providers determine the most effective therapy for their patients.
- Incorporating PrismRA into our clinical protocols directly supports our focus on improving outcomes while reducing the cost of care.
- We are proud to be collaborating with a technology-driven company like Trellis Rx to advance patient outcomes through PrismRA testing, said Alif Saleh, Scipher Medicine CEO.
- We partner with payers, providers, and pharma along the healthcare value chain to bring precision medicine to autoimmune diseases.
Retrieved on:
Friday, September 24, 2021
Sickle Cell Anemia, a Molecular Disease,
Solution,
Therapy,
Degenerative disease,
JD,
Patient,
Precision medicine,
Legal Affairs,
LinkedIn,
Twitter,
Associate,
Leadership,
McDermott,
Technology,
Intelligence,
General counsel,
Rheumatoid arthritis,
GLOBE,
Pharmaceutical industry WALTHAM, Mass., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of Sam A. Davis, JD, as General Counsel.
Key Points:
- WALTHAM, Mass., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of Sam A. Davis, JD, as General Counsel.
- We are very excited to welcome Sam to the Scipher team, said Alif Saleh, Chief Executive Officer of Scipher Medicine.
- Scipher is developing exciting and innovative novel solutions to some of the greatest challenges in healthcare today, using cutting edge technology, said Sam.
- Prior to joining Scipher, Sam was Associate General Counsel, Vice President Legal Affairs at EQRx, where he led all legal matters, including private and public financings, multiple global license and collaborations, and payer partnerships.
Retrieved on:
Wednesday, September 22, 2021
Goldman Sachs,
Sickle Cell Anemia, a Molecular Disease,
Degenerative disease,
Therapy,
Yale School of Management,
Doctor of Philosophy,
Patient,
Precision medicine,
LinkedIn,
Morgan Stanley,
Twitter,
Columbia University,
Growth,
Intelligence,
MBA,
Autoimmune disease,
Weiss,
Yale school,
Yale University,
Industry,
GLOBE,
Pharmaceutical industry,
Financial services WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of John Strumbos, Ph.D., MBA as Chief Financial Officer.
Key Points:
- WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of John Strumbos, Ph.D., MBA as Chief Financial Officer.
- John will be instrumental in guiding Sciphers financing and capital strategy as the company continues its rapid growth trajectory.
- We are thrilled to welcome John to the Scipher team, said Alif Saleh, Chief Executive Officer of Scipher Medicine.
- Scipher Medicine, a precision immunology company, holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data.
Retrieved on:
Monday, September 20, 2021
Adoption,
Sickle Cell Anemia, a Molecular Disease,
Pharmacy,
Degenerative disease,
Therapy,
Patient,
Precision medicine,
LinkedIn,
Twitter,
Strategic planning,
Myriad,
Myriad Genetics,
Intelligence,
Genetics,
Cambia Health Solutions,
Innovation,
RA,
Rheumatoid arthritis,
GLOBE,
Management,
Pharmaceutical industry WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today announces the addition of Chip Parkinson as Chief Commercial Officer of its diagnostic business.
Key Points:
- WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today announces the addition of Chip Parkinson as Chief Commercial Officer of its diagnostic business.
- We are incredibly excited to have Chip join the Scipher team, said Alif Saleh, Chief Executive Officer of Scipher Medicine.
- What attracted me to Scipher was the companys relentless focus on developing tests that both improve patient outcomes and reduce wasted spend in the healthcare system, said Chip.
- Scipher Medicine, a precision immunology company, holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data.
Retrieved on:
Thursday, September 16, 2021
Precision medicine,
Sickle Cell Anemia, a Molecular Disease,
Doctor,
Technology,
Consultant,
Patient,
LinkedIn,
Physician,
Therapy,
Rheumatoid arthritis,
TPA,
MBM,
RA,
Plasma protein binding,
Degenerative disease,
Twitter,
MBA,
Partnership,
GLOBE,
Intelligence,
TNF inhibitor,
Pharmaceutical industry Our products push the boundaries of current practices in managing healthcare costs, improving efficiencies, and the overall quality of care, said Ventegra CEO Robert.
Key Points:
- Our products push the boundaries of current practices in managing healthcare costs, improving efficiencies, and the overall quality of care, said Ventegra CEO Robert.
- PrismRA, a liquid molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.
- We partner with payers, providers, and pharma along the health care value chain to bring precision medicine to autoimmune diseases.
- As a Medical Benefit Manager (MBM), Ventegra is a new class-of-trade healthcare model that helps clients gain efficiencies, lower expenditures, and improve the overall quality of care.
Medical specialties,
Clinical medicine,
Medicine,
Rheumatology,
Autoimmune diseases,
Connective tissue diseases,
Arthritis,
Rheumatoid arthritis,
Precision medicine,
Sjögren syndrome,
Autoimmunity,
Lars Klareskog WALTHAM, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA blood test.
Key Points:
- WALTHAM, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA blood test.
- PrismRA is a first-of-its-kind molecular signature test that informs personalized treatment decisions for RA patients at any point in the clinical journey.
- PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.
- We partner with payers, providers, and pharma along the healthcare value chain to bring precision medicine to autoimmune diseases.
Medical specialties,
Clinical medicine,
Medicine,
Rheumatology,
Autoimmune diseases,
Connective tissue diseases,
Arthritis,
Immunology,
Rheumatoid arthritis,
TNF inhibitor,
Sjögren syndrome,
Autoimmunity PrismRA is the leading molecular signature test to help guide personalized therapy selection for rheumatoid arthritis.
Key Points:
- PrismRA is the leading molecular signature test to help guide personalized therapy selection for rheumatoid arthritis.
- The NETWORK-004 study met primary and secondary endpoints, with a molecular signature of non-response detected in 45% of therapy-nave patients and 40% of patients who have already started TNFi therapy.
- Most rheumatoid arthritis patients are prescribed the worlds largest selling drug class, TNFi therapy, yet the majority will not have an adequate response, said Alif Saleh, CEO Scipher Medicine.
- We partner with payers, providers, and pharma along the health care value chain to bring precision medicine to autoimmune diseases.
The study compared baseline PrismRA results with actual outcomes at six months using EULAR good response as the clinical outcome measure.
Key Points:
- The study compared baseline PrismRA results with actual outcomes at six months using EULAR good response as the clinical outcome measure.
- The study found a EULAR-based inadequate response in 37 out of the 68 patients, or 54.4%.
- The successful validation of the novel test for EULAR inadequate response in this treat-to-target setting is promising, said Johanna Withers , Ph.D., study co-author, and Principal Scientist at Scipher Medicine.
- PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.
The results were published both in Proceedings of the National Academy of Sciences and Life Science Alliance .
Key Points:
- The results were published both in Proceedings of the National Academy of Sciences and Life Science Alliance .
- By applying network biology and AI platform to clinico-genomic patient data, the research was compressed from three years to two months.
- Scipher Medicine, a precision immunology company, holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data.
- We partner with payers, providers, and pharma along the health care value chain to bring precision medicine to autoimmune diseases.
